Your browser doesn't support javascript.
loading
Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function.
Beyranvand Nejad, Elham; Labrie, Camilla; van der Sluis, Tetje C; van Duikeren, Suzanne; Franken, Kees L M C; Roosenhoff, Rueshandra; Arens, Ramon; van Hall, Thorbald; van der Burg, Sjoerd H.
Afiliación
  • Beyranvand Nejad E; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
  • Labrie C; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
  • van der Sluis TC; Department of Immunology, Leiden University Medical Center, Leiden University Medical Center, Leiden, The Netherlands.
  • van Duikeren S; Department of Immunology, Leiden University Medical Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Franken KLMC; Department of Immunology, Leiden University Medical Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Roosenhoff R; Department of Immunology, Leiden University Medical Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Arens R; Department of Immunology, Leiden University Medical Center, Leiden University Medical Center, Leiden, The Netherlands.
  • van Hall T; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
  • van der Burg SH; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Int J Cancer ; 148(1): 211-225, 2021 01 01.
Article en En | MEDLINE | ID: mdl-32875568
High serum levels of interleukin-6 (IL-6) correlate with poor prognosis and chemotherapy resistance in several cancers. The underlying mechanisms and its effects on immunotherapy are largely unknown. To address this, we developed a human papillomavirus type 16 (HPV16)-associated tumor model expressing IL-6 to investigate the impact of tumor-expressed IL-6 during cisplatin chemotherapy and HPV16 synthetic long peptide vaccination as immunotherapy. The effects of tumor-produced IL-6 on tumor growth, survival and the tumor microenvironment were analyzed. Our data demonstrated that tumor-produced IL-6 conferred resistance to cisplatin and therapeutic vaccination. This was not caused by a changed in vitro or in vivo growth rate of tumor cells, or a changed sensitivity of tumor cells to chemotherapy or T-cell-mediated killing. Furthermore, no overt differences in the frequencies of tumor-infiltrating subsets of T cells or CD11b+ myeloid cells were observed. IL-6, however, affected the systemic and local function of myeloid cells, reflected by a strong reduction of major histocompatibility complex (MHC) class II expression on all major myeloid cell subtypes. Resistance to both therapies was associated with a changed intratumoral influx of MHC class II+ myeloid cells toward myeloid cells with no or lower MHC class II expression. Importantly, while these IL-6-mediated effects provided resistance to the immunotherapy and chemotherapy as single therapies, their combination still successfully mediated tumor control. In conclusion, IL-6-mediated therapy resistance is caused by an extrinsic mechanism involving an impaired function of intratumoral myeloid cells. The fact that resistance can be overcome by combination therapies provides direction to more effective therapies for cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Interleucina-6 / Vacunas contra el Cáncer / Células Mieloides / Infecciones por Papillomavirus / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Interleucina-6 / Vacunas contra el Cáncer / Células Mieloides / Infecciones por Papillomavirus / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos